HALOZYME THERAPEUTICS, INC.
HALOCIK 0001159036 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR
At a glance · FY2025 (Q4)
Quality Score
Quality score
6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration
- Profitability53ROIC 15.7% (10% = solid, 20%+ = moat)
- Liquidity100Current Ratio 4.66 (above 1.5 = solid)
- Leverage0D/E 43.89 (under 0.5 = conservative)
- Efficiency31Asset Turnover 0.61x (1.0+ = capital-efficient)
- Growth100Revenue YoY +51.6% (10% = solid, 25%+ = elite)
- Margin Trend100Op Margin 61.5% · trend +5.4pts (4Q avg vs prior 4Q)
Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.
DCF intrinsic value
DCF intrinsic value
two-stage Gordon modelProject HALO's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.
Trailing 3-yr CAGR was 39.9%
10% is a common all-equity benchmark for US large-caps
Should be ≤ long-run GDP growth (~2.5% nominal)
5-year explicit projection + perpetuity terminal
| Year | Projected FCF | Discounted PV |
|---|---|---|
| +1 | $806M | $732M |
| +2 | $1.01B | $832M |
| +3 | $1.26B | $946M |
| +4 | $1.57B | $1.07B |
| +5 | $1.97B | $1.22B |
| Terminal | $26.88B | $16.69B |
DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.
Capital allocation · trailing 4 quarters
how the company spent its cashBalance sheet · 2025-12-31
latest filed snapshotRecent performance · 63 quarters
Drill down
HALO Sankey
See HALOZYME THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.
Open SankeyHALO Charts
63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open ChartsHALO Key Metrics
EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.
Open Key Metrics